Universe Pharmaceuticals Holds 2024 Annual Meeting, Approves Proposals
Ticker: UPC · Form: 6-K · Filed: Sep 27, 2024 · CIK: 1809616
| Field | Detail |
|---|---|
| Company | Universe Pharmaceuticals INC (UPC) |
| Form Type | 6-K |
| Filed Date | Sep 27, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $3,125,000, $0.01875, $140,625,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-meeting, corporate-governance, shareholder-approval
TL;DR
Universe Pharma shareholders greenlit all 9 proposals at the 2024 AGM on Sept 27.
AI Summary
Universe Pharmaceuticals INC held its 2024 Annual General Meeting on September 27, 2024, where shareholders approved all nine proposals presented. The meeting took place at 10:00 a.m. Beijing Time. The company is a foreign private issuer filing under the 1934 Act.
Why It Matters
The approval of all proposals at the annual general meeting signifies shareholder confidence and allows the company to proceed with its planned corporate actions for the upcoming year.
Risk Assessment
Risk Level: low — This filing is a routine report of an annual general meeting where all proposals were approved, indicating no immediate negative surprises.
Key Numbers
- 9 — Proposals Approved (Shareholders unanimously approved all nine proposals at the annual general meeting.)
Key Players & Entities
- Universe Pharmaceuticals INC (company) — Filer of the report and subject of the meeting
- September 27, 2024 (date) — Date of the 2024 Annual General Meeting
- Beijing Time (time_zone) — Time zone for the meeting
FAQ
What were the specific nine proposals approved at the 2024 Annual General Meeting?
The filing states that all nine proposals were adopted, but does not list the specific details of each proposal.
What is the significance of Universe Pharmaceuticals INC being a foreign private issuer?
As a foreign private issuer, the company files under the 1934 Act and may file annual reports under Form 20-F, indicating it is subject to different reporting requirements than domestic US companies.
Where is Universe Pharmaceuticals INC's principal executive office located?
The principal executive offices are located at 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China.
What is the fiscal year end for Universe Pharmaceuticals INC?
The fiscal year end for Universe Pharmaceuticals INC is September 30.
What is the SIC code for Universe Pharmaceuticals INC?
The Standard Industrial Classification (SIC) code for Universe Pharmaceuticals INC is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,029 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2024-09-27 16:05:20
Key Financial Figures
- $3,125,000 — ncreased, effective immediately, from US$3,125,000 divided into 150,000,000 Ordinary Share
- $0.01875 — ,000,000 Ordinary Shares of par value US$0.01875 each and 16,666,666.6666 preferred shar
- $140,625,000 — uo;) of par value US$0.01875 each, to US$140,625,000 divided into 6,750,000,000 Ordinary Sha
Filing Documents
- ea0215967-6k_universe.htm (6-K) — 42KB
- 0001213900-24-082702.txt ( ) — 43KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Universe Pharmaceuticals INC Date: September 27, 2024 By: /s/ Gang Lai Gang Lai Chief Executive Officer 3